Successful treatment of a mucous membrane pemphigoid in a young dog

Abstract

Mucous membrane pemphigoid was diagnosed in a 2.5-year-old male intact foxhound-beagle cross which was presented with an acute onset of non-pruritic, multifocal, slowly progressive erosive-ulcerative dermatitis predominantly affecting the nasal planum, eyelids and muzzle with multiple vesicles on the inner pinnae, oral mucosa and tongue. The diagnosis was based on clinical signs and histological examination of skin biopsies. The patient did not respond to immunosuppressive prednisolone therapy, but went into complete remission with oral doxycycline and niacinamide and stayed in remission on long-term exclusive niacinamide treatment.

Zusammenfassung

Bei einem 2,5-jährigen, männlich-intakten Foxhound-Beagle-Mischling mit akuter, multifokaler, langsam fortschreitender, erosiv-ulzerierender Dermatitis ohne Juckreiz wurde basierend auf klinischen Symptomen und histologischer Untersuchung von Hautbioptaten ein mukokutanes Pemphigoid diagnostiziert. Betroffen waren Nasenspiegel, Augenlider und Schnauze. Bläschen fanden sich auch an Ohreninnenseiten, Maulschleimhaut und Zunge. Der Patient sprach nicht auf eine immunsuppressive Therapie mit Prednisolon an. Mit oraler Gabe von Doxycyclin und Niacinamid ließ sich eine vollständige Remission erreichen und die Erkrankung blieb unter langfristiger ausschließlicher Therapie mit Niacinamid in Remission.

Key words

Subepidermal blistering - autoimmune skin disease - auto-antibodies - doxycycline - niacinamide vesicle - biopsy

Schlüsselwörter

Subepidermale Blasenbildung - autoimmune Hauterkrankung - Autoantikörper - Doxycyclin - Niacinamid - Bläschen - Biopsie

• References

• 1 Amber KT, Bloom R, Hertl M. A systematic review with pooled analysis of clinical presentation and immunodiagnostic testing in mucous membrane pemphigoid: association of anti-laminin-332 IgG with oropharyngeal involvement and the usefulness of ELISA. J Eur Acad Dermatol Venereol 2016; 30: 72-77
• 2 Amber KT, Valdebran M, Kridin K. et al. The role of eosinophils in bullous pemphigoid: a developing model of eosinophil pathogenicity in mucocutaneous disease. Frontiers in Medicine 2018; 10 (05) 201
• 3 Austin VH, Maibach HI. Immunofluorescence testing in a bullous skin disease in a dog. J Am Vet Med Assoc 1976; 168: 322-324
• 4 Banovic F, Linder KE, Uri M. et al. Clinical and microscopic features of generalized discoid lupus erythematosus in dogs (10 cases). Vet Dermatol 2016; 27: 488-e131
• 5 Bernard P, Vaillant L, Labeille B. et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol 1995; 131 (01) 48-52
• 6 Bruch-Gerharz D, Hertl M, Ruziska T. Mucous membrane pemphigoid: clinical aspects, immunopathological features and therapy. Eur J Dermatol 2007; 17 (03) 191-200
• 7 Chan LS, Ahmed AR, Anhalt GJ. et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138 (03) 370-379
• 8 Chhabra S, Minz RW, Saikia B. Immunofluorescence in dermatology. Indian J Dermatol Venereol Leprol 2012; 78: 677-691
• 9 Gordon RA, Mays A, Sambrano B. et al. Antibiotics used in nonbacterial dermatologic conditions. Dermatol Ther 2012; 25: 38-54
• 10 Hill PB, Boyer P, Lau P. et al. Epidermolysis bullosa acquisita in a great Dane. J Small Anim Pract 2008; 49: 89-94
• 11 Kasperkiewicz M, Zillikens D, Schmidt E. Pemphigoid diseases: Pathogenesis, diagnosis, and treatment. Autoimmunity 2012; 45 (01) 55-70
• 12 Kasperkiewic M, Sadik CD, Bieber K. et al. Epidermolysis bullosa acquisita: From pathophysiology to novel therapeutic options. J Invest Dermatol 2016; 136: 24-33
• 13 Kelly WN. How can I recognize an adverse drug event?. Medscape CME Pharmacists. 2008
• 14 Kourosh AS, Yancey KB. Pathogenesis of mucous membrane pemphigoid. Dermatol Clin 2011; 29 (03) 479-484
• 15 Kunkle G, Goldschmidt MH, Halliwell REW. Bullous pemphigoid in a dog: a case report with immunofluorescent findings. J Am Anim Hosp Assoc 1978; 14: 52-57
• 16 Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther Adv Drug Saf 2014; 5 (06) 229-241
• 17 Morris MO, Loeffler A, Davis MF. et al. Recommendations for approaches to meticillin-resistant staphylococcal infections of small animals: diagnosis, therapeutic considerations and preventative measures. Vet Dermatol 2017; 28: 304-e69
• 18 Naranjo CA, Busto U, Sellers EM. et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245
• 19 Olivry T. An autoimmune subepidermal blistering skin disease in a dog? The odds are that it is not bullous pemphigoid. Vet Dermatol 2014; 25: 316-318
• 20 Olivry T, Stanley MD, Schachter M. et al. A spontaneous canine model of mucous membrane (cicatricial) pemphigoid, an autoimmune blistering disease affecting mucosae and mucocutaneous junctions. J Autoimmun 2001; 16: 411-421
• 21 Olivry T, Rossi MA, Banovic F. et al. Mucocutaneous lupus erythematosus in dogs (21 cases). Vet Dermatol 2015; 26: 256-e55
• 22 Olivry T, Fine J, Dunston SM. et al. Canine epidermolysis bullosa acquisita: circulating autoantibodies target the aminoterminal non-collagenous (NC1) domain of collagen VII in anchoring fibrils. Vet Dermatol 1998; 9: 19-31
• 23 Olivry T, Jackson A. Diagnosing new autoimmune blistering skin diseases of dogs and cats. Clin Tech Small Anim Pract 2001; 16 (04) 225-229
• 24 Olivry T, Dunston SM, Zhang G. et al. Laminin-5 is targeted by autoantibodies in feline mucous membrane (cicatricial) pemphigoid. Vet Immunol Immunopathol 2002; 88: 123-129
• 25 Parker WM. Autoimmune skin diseases in the dog. Can Vet J 1980; 22: 302-304
• 26 Scott DW, Wolfe MJ, Smith CA. et al. The comparative pathology of non-viral bullous skin diseases in domestic animals. Vet Pathol 1980; 17: 257-281
• 27 Stannard AA, Gribble DH, Baker BB. A mucocutaneous disease in the dog, resembling pemphigus vulgaris in man. J Am Vet Med Assoc 1975; 166 (06) 575-582
• 28 Wiemelt SP, Goldschmidt MH, Greek JS. et al. A retrospective study comparing the histopathological features and response to treatment in two canine nasal dermatoses, DLE and MCP. Vet Dermatol 2004; 15: 341-348
• 29 Sacher C, Hunzelmann N. Cicatricial pemphigoid (mucous membrane pemphigoid): current and emerging therapeutic approaches. Am J Clin Dermatol 2005; 6 (02) 93-103
• 30 Sapadin AN, Fleischmajer R. Tetracyclines: Nonantibiotic properties and their clinical implications. J Am Acad Dermatolog 2006; 54 (02) 258-265
• 31 Taylor J, McMillan R, Shephard M. et al. World Workshop on Oral Medicine VI: a systematic review of the treatment of mucous membrane pemphigoid. Oral Medicine 2015; 120 (02) 161-171
• 32 Tham HL, Olivry T, Linder KE. et al. Mucous membrane pemphigoid in dogs: a retrospective study of 16 new cases. Vet Dermatol 2016; 27 (05) 376
• 33 Viviano KR. Update on immununosuppressive therapies for dogs and cats. Vet Clin Small Anim 2013; 43 (05) 1149-1170
• 34 Wohlrab J, Kreft D. Niacinamide – mechanisms of action and its topical use in dermatology. Skin Pharmacol Physiol 2014; 27: 311-315
• 35 Xu HH, Werth VP, Parisi E. et al. Mucous membrane pemphigoid. Dent Clin North Am 2013; 57 (04) 611-630